CellMiner: A web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set

Cancer Research

Volumn 72, Issue 14, 2012, Pages 3499-3511

  Reinhold, William C ^a,e   Sunshine, Margot ^a,b   Liu, Hongfang ^a,c   Varma, Sudhir ^a,d   Kohn, Kurt W ^a   Morris, Joel ^a   Doroshow, James ^a   Pommier, Yves ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENERAL DYNAMICS   (United States)

^c MAYO CLINIC   (United States)

^d HiThru Analytics LLC   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CHROMOMYCIN; DOXORUBICIN; ERLOTINIB; GEFITINIB; LAPATINIB; MICRORNA; MICRORNA 17 92; ROMIDEPSIN; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER GENETICS; CELLMINER; COMPUTER MODEL; DRUG APPROVAL; DRUG IDENTIFICATION; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GENE CLUSTER; GENE SEQUENCE; GENETIC DATABASE; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; HUMAN CELL; INFORMATION PROCESSING; NCI 60 CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WEB BROWSER;

ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG EVALUATION; GENE EXPRESSION; GENOMICS; HUMANS; INFORMATION STORAGE AND RETRIEVAL; INTERNET; MICROARRAY ANALYSIS; MICRORNAS; NATIONAL CANCER INSTITUTE (U.S.); RNA; UNITED STATES;

EID: 84863910171     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1370     Document Type: Article

References (46)

1. Holbeck SL, Collins JM, Doroshow JH. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 2010;9:1451-60.
2. Shoemaker R. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23. (Pubitemid 44450469)
3. Bussey K, Chin K, Lababidi S, Reimers M, Reinhold W, Kuo W, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006;5:853-67. (Pubitemid 43724584)
4. Roschke A, Tonon G, Gehlhaus K, McTyre N, Bussey K, Lababidi S, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-47. (Pubitemid 38064038)
5. Ikediobi O, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of twenty-four known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12. (Pubitemid 44848987)
6. Lorenzi P, Reinhold W, Varma S, Hutchinson A, Pommier Y, Chanock S, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 2009;8:713-24.
7. Scherf U, Ross D, Waltham M, Smith L, Lee J, Tanabe L, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44. (Pubitemid 30132190)
8. Shankavaram U, Reinhold W, Nishizuka S, Major S, Morita D, Reimers M, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6:820-32. (Pubitemid 46554552)
9. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 2010;9:1080-91.
10. Blower PE, Verducci JS, Lin S, Zhou J, Chung J, Dai Z, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007;6:1483-91. (Pubitemid 46954015)
11. Nishizuka S, Charboneau L, Young L, Major S, Reinhold W, Waltham M, et al. Proteomic profiling of the NCI60 cancer cell lines using new high-density 'reverse-phase' lysate microarrays. Proc Natl Acad Sci U S A 2003;100:14229-34. (Pubitemid 37499219)
12. Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, et al. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther 2009;8:1878-84.
13. Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, et al. Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 2010;70:2191-203.
14. Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther 2010;9:3105-14.
15. Zoppoli G, Douarre C, Dalla Rosa I, Liu H, Reinhold W, Pommier Y. Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. Nucleic Acids Res 2011;39:6620-32.
16. Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly JW Jr, Monks A, et al. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene 2012;31:403-18.
17. Reinhold WC, Erliandri I, Liu H, Zoppoli G, Pommier Y, Larionov V. Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability. PLoS One 2011;6:e25991.
18. Zeeberg BR, Reinhold W, Snajder R, Thallinger GG, Weinstein JN, Kohn KW, et al. Functional categories associated with clusters of genes that are co-expressed across the NCI-60 cancer cell lines. PLoS One 2012;7:e30317.
19. Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 2009;10:277.
20. Wu Z, Irizarry RA. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol 2005;12:882-93. (Pubitemid 41170488)
21. Larsen RJ, Marx ML. An introduction to mathematical statistics and its applications. 3rd ed. Englewood Cliffs, NJ: Prentice Hall; 2000.
22. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-8. (Pubitemid 20213251)
23. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95:15665-70. (Pubitemid 29018757)
24. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-37. (Pubitemid 39485685)
25. He L, Thomson JM, Hemann MT, Hernando-Monge E,Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33. (Pubitemid 40839734)
26. Kohn KW, Zeeberg BR, Reinhold WC, Sunshine M, Luna A, Pommier Y. Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell-matrix attachments in migrating cells. PLoS One 2012;7:e35716.
27. Reinhold WC, Reimers MA, Lorenzi P, Ho J, Shankavaram UT, Ziegler MS, et al. Multifactorial regulation of E-cadherin expression: an integrative study. Mol Cancer Ther 2010;9:1-16.
28. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010;29:3490-500.
29. Montserrat N, Gallardo A, Escuin D, Catasus L, Prat J, Gutierrez-Avigno FJ, et al. Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol 2011;42:103-10.
30. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7:1267-78. (Pubitemid 32607360)
31. Bolos V, Peinado H, Perez-Moreno M, Fraga M, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003;116:499-511. (Pubitemid 36231290)
32. Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, et al. MiR-200 family regulates TGF-{beta}1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 2012;302:F369-79.
33. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010;126:2575-83.
34. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012;482:347-55.
35. van Haaften G, Agami R. Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 2010;24:1-4.
36. Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, et al. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by Pglycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther 2005;313:268-76. (Pubitemid 40411351)
37. Chitnis MP, Joshi SS, Gude RP, Menon RS. Induced resistance in leukaemia L1210 to adriamycin and its cross-resistance to vincristine and bouvardin. Chemotherapy 1982;28:209-12. (Pubitemid 12127452)
38. Yagyu R, Furukawa Y, Lin YM, Shimokawa T, Yamamura T, Nakamura Y. A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer. Int J Oncol 2004;25:1343-8.
39. Nishizuka S, Chen S, Gwadry F, Alexander J, Major S, Scherf U, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003;63:5243-50. (Pubitemid 37139837)
40. Kahlert C, Klupp F, Brand K, Lasitschka F, Diederichs S, Kirchberg J, et al. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci 2011;102:1799-807.
41. Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, et al. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer 2011;10:340-7.
42. Dees EC, Rowinsky EK, Noe DA, O'Reilly S, Adjei AA, Elza-Brown K, et al. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer. Invest New Drugs 2003;21:75-84. (Pubitemid 36628487)
43. Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 2011;71:445-53.
44. Yoshino T, Yamazaki K, Hamaguchi T, Shimada Y, Kato K, Yasui H, et al. Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. Anticancer Res 2012;32:973-9.
45. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of a mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92. (Pubitemid 19175145)
46. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 2006;75:93-109. (Pubitemid 44118027)